ROBERT A. BLOUIN, Dean
Robert A. Blouin, Effects of Infectious Disease and Trauma on Altered Physiologic States (i.e., Aging and Obesity), and the Expression and Regulation of Drug Metabolizing Enzymes
Kim L. R. Brouwer (62) Hepatobiliary Drug Disposition, Mechanisms of Drug Absorption and Transport, Clinical Pharmacokinetics
William H. Campbell (83) Pharmacoepidemiology, Pharmacy and Health Care Policy
Dale B. Christensen (105), Pharmacy and Drug-Related Outcomes Research, Drug Policy, Patient Compliance, Pharmacoeconomics
Frederick M. Eckel (9) Exploration and Role Development of Pharmacist as Health Team Members
B. W. Hadzija (19) Analysis of Drugs and Their Metabolic Degradation Products
Anthony J. Hickey (86) Pulmonary Drug Delivery, Aerosol Formulations
Leaf Huang (121) Gene Therapy, Targeted Drug Delivery
Harold Kohn (106) Organic, Medicinal, and Bio-Organic Chemistry; Mechanisms of Biochemical and Medicinal Processes; Synthesis and Investigation of Heterocyclic Compounds of Medicinal Interest
Kuo-Hsiung Lee (13) Medicinal Chemistry of Bioactive Natural Products and Synthetic Analogs Including Antitumor, Anti-AIDS, Antimalarial, Antihepatic, Anti-inflammatory, Anti-Arthritis and Antiviral Agents; Antifungal Antibiotics; Insect Antifeedants; Chinese Herbal Medicine
Michael D. (Mick) Murray (119) Medication Management Programs, Patient Adherence to Prescription Medications, Pharmacoepidemiology, Pharmaceutical Outcomes Research
Gary M. Pollack (53) Pharmacokinetics and Pharmacodynamics of CNS Active Agents, Pharmacokinetic Model Development, Toxicokinetics
Dhiren R. Thakker (87) Mechanisms of Drug Transport, Pro-Drug Strategies for Enhanced and Targeted Drug Delivery, Disposition of Macromolecules (e.g., Genes)
Alexander Tropsha (81) Molecular Modeling, Computer-Assisted Drug Design, Molecular Dynamics of Proteins, Protein Folding
Kenneth F. Bastow (84) Design and Testing of Antiviral/Anticancer Drugs
Susan J. Blalock (115) Psychosocial Aspects of Chronic Illness, with Emphasis on Musculoskeletal Disorders
Stephen M. Caiola (14) Evaluation of Pharmacy Service Delivery Models and Therapeutic Regimens in Ambulatory Care Settings
Moo J. Cho (79) Targeted Drug Delivery
James E. Hall (109) Development of Anti-Parasitic and Anti-Viral Agents
Timothy J. Ives (90) Ambulatory Care, Pharmacy Practice
Angela D.M. Kashuba (114) Pharmacogenetics, Pharmacokinetics and Pharmacodynamics of Antiretroviral Agents, Influence of Cytokines on Drug-Metabolizing Enzymes
Richard J. Kowalsky (26) Radiopharmaceuticals
Celeste M. Lindley (58) Pharmacogenetics, Pharmacokinetics, and Pharmacodynamics of Antineoplastic Agents and Coagulation Products; Drug Metabolism
Matthew L. Maciejewski (123) Health Economics, Medicare Managed Care, Diabetes Costs and Outcomes, Obesity-Related Quality of Life and Costs
J. Herbert Patterson (47) Pharmacokinetic Evaluation of Cardiovascular Drugs
A. Wayne Pittman (30) Hypertension, Clinical Pharmacokinetics, Cardiology and Drug Administration
Ralph H. Raasch (32) Infectious Diseases, Parenteral Nutrition
Robert P. Shrewsbury (39) Biopharmaceutics
Scott Singleton (116) Bio-Organic and Biophysical Chemical Investigations of the Mechanisms DNA Repair, Directed Evolution of Novel Enzymes, Development of Alternate Strategies for Targeting Drug-Resistant Pathogenic Micro-organisms
Betsy L. Sleath (91) Provider-Patient Communication, Drug Utilization Review, Patient Compliance, Pharmacoepidemiology
Philip C. Smith (85) Pharmacokinetics, Drug Metabolism
Dennis M. Williams (92) Pharmacokinetics and Pharmacodynamics, Inhalation Therapy for Pulmonary Disease, Hypertension
Richard A. Hansen, Prescription Drug Insurance, Pharmaceutical Outcomes, Pharmacoepidemiology, Direct-to-Consumer Advertising
Roy Hawke (118) Pharmacogenetics of Drug Metabolism and Liver Disease, Lipotoxicity, Drug Toxicity
Michael B. Jarstfer (112) Telomerase and High-Throughput Drug Discovery
Andrew Lee (111) Structural Biology, NMR Spectroscopy, Protein Dynamics, Biophysical Dissection of Proteins and Protein-Ligand Interactions
Jian Liu (108) Carbohydrate Biochemistry, Structural and Functional Relationships of Heparan Sulfate
Rihe Liu (113) Proteomics and Functional Genomics
Mary T. Roth, Quality of Medication Use and Clinical Outcomes in Older Adults
Feng Liu, Gene and Drug Delivery
Susan Morris-Natschke (102) Design, Synthesis, and Structural Optimization of Antiviral Phospholipids
Arlene P. Bridges, Mass Spectrometry
Lucila Garcia-Contreras, Aerosol Drug Delivery
Alexander Golbraikh, Informatics
Mary F. Paine, Pharmacokinetics, Drug Metabolism and Transport, Pharmacogenetics
Hongbing Wang (122), Drug Metabolism and Transport, Drug Resistance in Cancer
Gary M. Armstrong, Public Policy, Deception in Advertising, Sales Force Management
Allen E. Cato, Clinical Drug Trials, Pediatric Diseases, and Pulmonary Medicine
Peter Gal, Pediatric Pharmacotherapy
J. Heyward Hull, Cardiovascular Pharmacology, Clinical Pharmacokinetics, Study Design and Analysis
Kimberly H. Deloatch, Educational Media and Instructional Design
Robert E. Dupuis, Clinical Pharmacokinetics, Transplantation
Deborah Montague, Cardiovascular Drug Therapy
J. Robert Powell, Clinical Pharmacokinetics and Drug Metabolism
William N. Zelman, Health Finance
Colleen Gresham, Drug Utilization Review
Amanda H. Corbett, Pharmacology of Antiretrovirals, Opportunistic Infection Therapies in Resource Poor Countries
Stefanie P. Ferreri, Evaluating Pharmaceutical Care in the Community Pharmacy Setting
Jo Ellen Rodgers, Cardiovascular and Critical Care Drug Therapy
Arnold Brossi, Synthesis and Study of Biologically Active Natural Products, Drugs Useful in Malaria Chemotherapy
Patricia Bush, Pediatric and Adolescent Health
Barry Goz, Drug Resistance in Cancer Cells
Michael Cory, Design, Synthesis, and Binding Studies of DNA Intercalating Agents, Quantitative Structure-Activity Relationships, Computer Applications to Drug Design
Arnold D. Kaluzny, Health Policy
Andrew T. McPhail, X-ray Crystal Structure Analysis of Naturally Occurring Compounds and Their Analogs, Synthesis and Structural Studies of Boron-Containing Amino Acids and Peptide Analogs
James Swarbrick, Physical Pharmacy, Biopharmaceutics
Hugh H. Tilson, Pharmacoepidemiology
Raymond J. Townsend, Pharmacoeconomics
Phillip Carl, Mechanisms of Drug Resistance in Cancer Chemotherapy and in Developing New Pharmacological Approaches to This Problem by Studying the Mechanisms of Genetic Recombination and Gene Amplification
Kun Chae, Receptor Binding Involving Estrogen and Other Synthetic Estrogenic Compounds
James Crow, Pulmonary and Hematology Inflammation
Donald K. Knight, Pharmaceutical Industry
Thomas R. Konrad, Primary Care, Health Services Research
John E. Paul, Pharmacoeconomics, Health Policy, Pharmacoepidemiology
Sue Tolleson-Rinehart, Health Policy
Kenneth R. Brouwer, Drug Metabolism, Pharmacokinetics
Michael O. Calloway, Mental Health, Substance Abuse
Robert A. Casper, Evaluation and Development of Polymeric Materials for Use in Controlled Drug Delivery and Novel Primary Drug Packaging
Lawrence L. Gan, Drug Metabolism, Pharmacokinetics
William Gillespie, Theoretical and Computer Analysis of Pharmacokinetic Systems
Keith A. Johnson, Research and Development in Chemical Engineering, Biloid and Interface Science, Aerosol Science, and Pharmaceutical Science
Stanley Levy, Cosmetic Science and Technology
Alan Parr, Pharmaceutics
Rukmini Rajagopalan, Pharmacoeconomics
Michiel Van Oort, Inhalation Product Development
Chris Wheeler, Design and Implementation of Data Management Systems for Drug Discovery Efforts
Khalid S. Ishaq
Tom S. Miya
G. Joseph Norwood
Claude Piantadosi
LeRoy D. Werley Jr.
Jack K. Wier
The School of Pharmacy offers graduate curricula leading to the master of science and doctor of philosophy degrees in pharmaceutical sciences. Graduate study may be concentrated in disciplinary areas represented by the divisions of medicinal chemistry and natural products, molecular pharmaceutics, pharmaceutical outcomes and policy, and pharmacotherapy and experimental therapeutics.
Instruction emphasizes contemporary research methods and results and is given by means of lectures, recitations, and seminars combined with intensive laboratory-based research. The excellent rapport that exists between schools, departments, institutes, and centers within the University facilitates interdisciplinary collaborative research by graduate students and faculty. The graduate degree programs also benefit from faculty affiliations with GlaxoSmithKline, Inc., the Research Triangle Institute, Duke University, the Wake Forest University School of Medicine, and many other organizations in the Research Triangle Park area.
The School of Pharmacy occupies Beard and Kerr Halls, which are located on the Health Sciences campus, together with the Schools of Dentistry, Medicine, Nursing, and Public Health. The Health Sciences Library has an outstanding collection of books and journals as well as computer/support services. Appropriate use also is made of the library and laboratory facilities in other University departments.
Medicinal chemistry is an interdisciplinary science. It applies and extends the basic concepts of chemistry, biochemistry, and pharmacology to the investigation of biomedical problems. Areas of study include structure-activity relationships, drug-receptor interactions, and synthetic drug design. Studies also may include biochemical mechanisms of drug interaction and drug toxicity, isolation of compounds from natural sources, and development of analytical methods that apply to all of the above areas of research. Specific research programs within the division focus on isolation of bioactive natural products and synthesis of related analogs, computational chemistry and molecular modeling, neurobiological proteins as targets for drug design, NMR-based techniques to study proteins, proteonomics, and nuclear protein enzymology.
Medicinal chemistry is a multidisciplinary field that requires understanding of organic chemistry and related biomedical disciplines such as biochemistry, molecular biology, structural biology, pharmacology, and physiology. It interfaces with each of these disciplines and with the use of current methodologies, focusing on learning disease pathways and how drugs function. Research techniques including synthesis, spectroscopy, biochemistry, molecular biology, and computational chemistry are linked to identify new therapeutic agents, targets, and the pathways by which drugs express their functions. Along with other important facilities, the division has specialized laboratories that conduct cutting-edge research. Focus groups include cancer chemotherapy, computer-aided drug design, enzymology, glycobiology, molecular modeling, natural products, neurochemistry, parasitology, and structural biology.
MS and PhD programs are offered in medicinal chemistry and natural products.
Molecular pharmaceutics represents interdisciplinary specialties encompassing a range of scientific endeavors, including: (1) the design, fabrication, evaluation, use of, and delivery strategies for dosage forms; (2) elucidation of the behavior of pharmacologic agents in biologic systems; (3) determination of the ability of pharmacologic agents to reach the relevant site of biologic effect; and (4) determination of the time course of biologic activity. These areas of specialization represent critical steps in the development of new therapeutic agents, the evaluation of new and existing drugs, and the optimal clinical use of pharmacologic agents.
Students in the Division of Molecular Pharmaceutics are required to participate in a common core of entry-level graduate courses. This core provides a broad perspective of the pharmaceutical sciences, as well as an appreciation for how different subdisciplines interact. Many dissertation projects are collaborative in nature and rely upon interactions with faculty in other divisions of the School of Pharmacy, as well as with colleagues in the School of Medicine, the Department of Chemistry, or at pharmaceutical companies or institutions located in the Research Triangle Park area.
Research and education in the Division of Pharmaceutical Outcomes and Policy (DPOP) emphasizes an interdisciplinary approach to solving problems of developing, evaluating, and distributing pharmaceutical products and services. Faculty research interests and course offerings reflect this interdisciplinary orientation.
Education and research in the division draws heavily upon expertise in numerous fields such as health policy, epidemiology, economics, and health behavior. DPOP emphasizes research in evaluation of pharmaceutical care and/or pharmaceutical technologies. This includes assessment of processes and outcomes of care from economic, humanistic, and clinical perspectives. Assessing and valuing outcomes in the pharmaceutical area is a vital part of the broader mission to improve the performance of the health care system. This is often exemplified in the formation and evaluation of drug policies.
The Division of Pharmacotherapy and Experimental Therapeutics offers a PhD program in the pharmaceutical sciences with a focus on translational research in experimental therapeutics. The goal of this program is to develop an individual who is capable of integrating biomedical and pharmaceutical sciences while maintaining expertise as a clinician. The focus of the program is the development of basic research skills that facilitate evaluation of mechanisms of disease processes and drug therapy. In addition, ongoing clinical experience and advanced course work in pharmacotherapy are integral parts of this program. Students work closely with faculty members who play an active role in the In Vitro In Vivo Correlates of Drug Disposition Scholarly Program, which utilizes preclinical models of absorption, distribution, metabolism, and elimination to predict the in vivo disposition of therapeutic agents. Strong therapeutic areas include oncology, infectious diseases/HIV, cardiology, and neuropsychopharmacology. Core course work includes molecular biology, biostatistics, analytical methodology, and advanced pharmacokinetics/pharmacodynamics. Research projects must include an in vitro and an in vivo component.
Applicants who have completed a standard collegiate curriculum in pharmacy, chemistry, biochemistry, biology, or in an allied field in the University, or in other universities or colleges having curricula acceptable to the UNC-Chapel Hill Graduate School, are eligible for admission to the graduate program in Pharmaceutical Sciences. Applications for admission must be supported by scores on the Graduate Record Examination, letters of recommendation, and a statement of personal goals as they relate to graduate study at the UNC-Chapel Hill School of Pharmacy.
The Graduate School online application (gradschool.unc.edu) is the standard means of applying for admission. Inquiries concerning admission to programs in the pharmaceutical sciences may be directed to the Office of Research and Graduate Education, CB# 7360, 29 Beard Hall, Chapel Hill, NC 27599-7360.
Graduate teaching and research assistantships in the School of Pharmacy provide a stipend of $21,000 for twelve months' service. All awards are made on a competitive basis with consideration given to the applicant's academic record and Graduate Record Examination scores. Information concerning these assistantships, fellowships, and traineeships may be obtained by writing directly to the Office of Research and Graduate Education, School of Pharmacy.
MEDC 821 [121] CHEMISTRY OF NATURAL PRODUCTS (3). Prerequisites, CHEM 466 or equivalent and permission of the instructor. An introduction to the isolation, structure determination, biosynthesis, and synthesis of bioactive natural products; emphasis on aspects relating to medicinal chemistry. Three hours a week. Spring or fall. Lee, staff.
MEDC 842 [156] THERAPEUTIC PROTEINS (1). This course covers applications of modern information theory and information technologies to biomolecular systems. The core of this course is an overview and practical applications of methods and techniques for the analysis of nucleic acid and protein sequences, sequence-structure, and sequence-function correlations.
MEDC 900 [141] INTRODUCTION TO RESEARCH IN MEDICINAL CHEMISTRY (1-3). Prerequisites, CHEM 261, 262, permission of the instructor. One conference and three or more laboratory hours a week. Fall and spring. Staff.
MEDC 804 [168] DRUG DISCOVERY TARGETS I (3). Prerequisites, CHEM 261, 262. Introduction to the principles of design and discovery of effective therapeutic agents. Concepts of physical chemistry, pharmacokinetics and disposition, and analytical techniques in the context of drug design. Spring. Staff.
MEDC 805 [275] MOLECULAR MODELING (BIOC 805) (3). Prerequisites, MATH 231-232, CHEM 481, permission of the instructor. Introduction to Computer-Assisted Molecular Design (CAMD) of small molecules. Emphasis on the practical use of molecular and quantum mechanics programs (MM2, MNDO, GAUSSIAN). Two lecture and three to four laboratory hours a week. Fall. Tropsha.
MEDC 806 [276] MACROMOLECULAR MODELING (BIOC 806) (3). Prerequisites: MATH 231-232, CHEM 430 or equivalent. Introduction to modeling and simulation techniques for biological macromolecules. Two lecture and three to four laboratory hours per week. Spring. Tropsha.
MEDC 822 [244] SELECTED TOPICS IN NATURAL PRODUCTS (2). Prerequisites, CHEM 466 and 468. Discussions of important recent developments in the chemistry of natural products of biomedical significance. Spring. Lee, staff.
MEDC 833 [169] MOLECULAR TARGET-BASED DRUG DISCOVERY (3). Prerequisite, MEDC 804. An integrated introduction to molecular target-based drug discovery including bioactive natural products, neuropharmacology, chemical biology and recent advances and techniques in drug discovery. Fall. R. Liu.
MEDC 836 [243] SELECTED TOPICS IN SYNTHETIC MEDICINAL CHEMISTRY (2). Prerequisite, CHEM 460 or equivalent. Discussions from current literature on the strategy and techniques involved in the synthesis of drug molecules. Two lecture hours a week. Spring and fall. Lee, staff.
MEDC 899 [361] SEMINAR (1). Fall and spring.
MEDC 991 [391] RESEARCH IN MEDICINAL CHEMISTRY (1-5). One conference and nine laboratory hours a week per course. Fall or spring. Staff.
MEDC 993 [393] MASTER'S THESIS (3). Fall and spring. Staff.
MEDC 994 [394] DOCTORAL DISSERTATION (3). Fall and spring. Staff.
MOPH 801 [107] NUCLEAR PHARMACY 1 (3). Prerequisites, PHCY 411 and permission of the instructor. Basic principles of radiation physics, instrumentation, radiation safety, and radiation biology. Fall. Kowalsky.
MOPH 802 [108] NUCLEAR PHARMACY 2 (3). Prerequisites, MOPH 801 and permission of the instructor. Chemical principles underlying the preparation, regulatory control, and use of radioactive drugs in nuclear medicine. Spring. Kowalsky.
MOPH 810 [155] DRUG METABOLISM (3). Prerequisite, permission of the instructor. Introduction to the use of concepts, chemistry, enzymology, and techniques in drug metabolism for the design and development of safe and effective therapeutic agents. Spring. (Odd years.) Thakker.
MOPH 840 [171] INTRODUCTION TO RESEARCH (1-3). Prerequisite, permission of the instructor. Students participate in research projects designed to introduce them to research opportunities in the pharmaceutical sciences. Fall and spring. Staff.
MOPH 850 [191] PHARMACEUTICAL ANALYSIS (1). Prerequisite, permission of the instructor. Introduction to quantitative instrumental analysis in pharmaceutics. One lecture hour a week. Fall. (Even years.) Smith.
MOPH 855 [156] PRINCIPLES OF PHARMACOKINETICS (3). Prerequisites: PHCY 413 or equivalent, permission of the instructor. Introduction to pharmacokinetic theory, mathematical model development, and data analysis techniques. Fall. (Odd years.) Pollack, Brouwer.
MOPH 856 [256] ADVANCED PHARMACOKINETICS AND PHARMACODYNAMICS (4). Prerequisites, MOPH 855, permission of the instructor. Advanced treatment of contemporary pharmacokinetic theory and application, with emphasis on model development, analytical approaches to parameter estimation, and experimental design/data analysis. Spring. (Even years.) Pollack, Brouwer.
MOPH 864 [165] ADVANCES IN DRUG DELIVERY (4). Prerequisites: PHCY 410, 411, or equivalent, CHEM 430 or equivalent, permission of the instructor. Elucidation of physiochemical and transport properties of the drug molecule as the determinant of method and route of drug delivery. Fall. (Even years.) Cho.
MOPH 865 [265] TRENDS IN DRUG DELIVERY RESEARCH (3). Prerequisite, MOPH 864. An interactive course in which students actively participate by critical evaluation and discussion of current literature in the field of drug delivery. Spring. (Odd years.) Staff.
MOPH 890 [253] SPECIAL TOPICS IN ADVANCED PHARMACEUTICS (Var.). Prerequisite, permission of the instructor. A lecture and/or laboratory course designed to present new concepts and innovations in the area of drug delivery and disposition. Fall and spring. Staff.
MOPH 899 [361] SEMINAR (1). Fall and spring. Staff.
MOPH 991 [391] RESEARCH (Var.). Graduate course consisting of laboratory-based research, conferences with the major professor, and library investigations relating to research. One conference and nine laboratory hours a week per course. Fall and spring. Staff.
MOPH 993 [393] MASTER'S THESIS (3). Fall and spring. Staff.
MOPH 994 [394] DOCTORAL DISSERTATION (3). Fall and spring. Staff.
DPOP 800 [180] PHARMACEUTICAL RESEARCH, DEVELOPMENT, AND MARKETING (HPAA 650) (3). This course acquaints students with the internal and external environments influencing decision making and management in the discovery, development, and marketing of new pharmaceutical products. The course focuses on the pharmaceutical industry with invited lectures by experienced scientists, regulators, policy analysts, and corporate managers from the industry. Three lecture hours a week. Spring. (Even years.) Smith.
DPOP 801 [251] PHARMACOECONOMICS (HPAA 653) (3). This course focuses on the empirical investigation of the economic and health impact of major pharmaceutical policies, regulations, market conditions, prescription drug use, and pharmaceutical care. Spring. Liu.
DPOP 803 [253] SOCIAL AND BEHAVIORAL ASPECTS OF PHARMACEUTICAL USE (2). This course will draw upon medical sociology and health psychology to familiarize students with core theories, research, measures, and design issues relevant to conducting social/behavioral research in pharmaceutical use. Fall. Sleath.
DPOP 804 [254] INFORMATICS: USE OF LARGE HEALTH CARE DATABASES (2). Interdisciplinary course providing practical training in the analysis of large, secondary databases containing physician, hospital, and pharmaceutical data. Course topics include data preparation, algorithm development, quality control, and dataset limitations. Fall. (Odd years.) Smith.
DPOP 805 [255] PATIENT-REPORTED OUTCOMES: THEORY, METHODS, AND APPLICATIONS (3). Course examines theoretical and methodological issues related to the assessment of patient reported outcomes, including health-related quality-of-life, in pharmaceutical research. Current and potential applications are highlighted. Spring. (Even years.) Blalock.
DPOP 806 [260] PHARMACEUTICAL POLICY (3). Course examines policies that influence pharmacy. Structured methods of policy analysis are examined and used to assess theoretic and analytic applications for evaluating pharmaceutical policy. Fall. (Even years.) Hansen.
DPOP 899 [361] SEMINAR (1). Fall and spring. Staff.
DPOP 901 [190] SELECTED TOPICS IN PHARMACEUTICAL OUTCOMES AND POLICY (1-3). A reading and/or special projects course for both undergraduate and graduate students interested in pursuing additional work in the administrative and social sciences as they pertain to pharmacy practice. One to three hours a week. Spring and fall. Staff.
DPOP 902 [203] METHODS IN PHARMACEUTICAL OUTCOMES RESEARCH (3). Includes formulating a research question, stating aims and hypothesis. Students are introduced to formulating a research strategy to write the background of the protocol, developing a research methodology, addressing measurement issues, selecting an appropriate design, and performing statistical analysis and power calculations. Three lecture hours a week. Fall. Staff.
DPOP 991 [391] RESEARCH IN PHARMACEUTICAL OUTCOMES AND POLICY (1-6). Consists of laboratory work, conferences with the major professor, and library investigations relating to research. Fall and spring. Staff.
DPOP 993 [393] MASTER'S THESIS (3). Fall and spring. Staff.
DPOP 994 [394] DOCTORAL DISSERTATION (3). Fall and spring. Staff.
DPET 813 [185] CARDIOVASCULAR PHARMACY (3). Provides an in-depth discussion of the pharmacotherapy of major cardiovascular diseases such as hypolipidemia, hypertension, ischemic heart disease, heart failure, and arrhythmias. Fall. Patterson.
DPET 821 [250] PRINCIPLES OF PHARMACY PRACTICE (3). Prerequisite, PHPR 249. Students discuss the modern role of the hospital pharmacist and how the role integrates progressive management with innovative services. The problems with implementing these programs are evaluated. Three lecture hours a week. Spring. Eckel.
DPET 822 [201] ADVANCED CLINICAL PHARMACY (3). Discussions, workshops, and lectures to develop the student's skills and abilities to make therapeutic recommendations, utilize drug literature, educate patients and health professionals, and record observations, plans, and actions in a problem-oriented record. Fall and spring. Lindley.
DPET 830 [210] INTRODUCTION TO DEVELOPMENT (2). Includes preclinical drug safety evaluation, preclinical pharmacology, design of protocols for Phases I-IV, FDA guidelines for clinical study, preparation of study plan, statistics in clinical trials, data analyzing, and FDA interactions with industry. Fall. Cato.
DPET 831 [211] DESIGN AND ANALYSIS OF CLINICAL DRUG TRIALS (2). Discussion of approaches to data analysis of clinical drug studies. Common study designs and their implementation are reviewed. Two lecture hours a week. Spring. Staff.
DPET 840 [200] ADVANCED PHARMACOTHERAPY (3). A modular approach to advanced level pharmacotherapy. Course work using the Pharmacotherapy Self Assessment Program (PSAP) aimed at improving clinical skills and reviewing standards of practice. Fall and spring. Lindley.
DPET 899 [361] SEMINAR (1). Fall and spring. Staff.
DPET 900 [391] RESEARCH IN PHARMACY PRACTICE (1-5). Consists of conferences with major professor; library, laboratory and/or field investigations relating to research. Professor in charge is responsible for the assignments and approval of the subject and character of the degree paper. Staff.
DPET 994 [394] DOCTORAL DISSERTATION (3). Fall and spring. Staff.
PHCY 800 [192] APPLIED PHARMACEUTICAL STATISTICS (3). Application of statistical analysis concepts and tools including probability, statistical inference, and regression analysis. Experimental design and statistical modeling approaches appropriate to common pharmaceutical research scenarios.
PHCY 801 [195] RESEARCH METHODS (2). Overview of the research process, including hypothesis testing, scientific writing, construction of research proposals and research ethics. Fall. Staff.